Domperidone: a peripherally acting dopamine2-receptor antagonist
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of domperidone in the treatment of gastrointestinal motility disorders and emesis. DATA SOURCES: MEDLINE and Excerpta Medica online databases were searched to identify published reports. STUDY SELECTION: Domperidone has be...
Gespeichert in:
| Veröffentlicht in: | Annals of Pharmacotherapy 1999-04, Vol.33 (4), p.429-440 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 440 |
|---|---|
| container_issue | 4 |
| container_start_page | 429 |
| container_title | Annals of Pharmacotherapy |
| container_volume | 33 |
| creator | Barone, JA |
| description | OBJECTIVE:
To review the pharmacology, pharmacokinetics, efficacy, and safety of domperidone in the treatment of gastrointestinal motility disorders and emesis.
DATA SOURCES:
MEDLINE and Excerpta Medica online databases were searched to identify published reports.
STUDY SELECTION:
Domperidone has been marketed worldwide outside the US since 1978, and extensive clinical data for this drug are available. This review focuses on the clinical experience from controlled studies of domperidone in the treatment of motility disorders, particularly diabetic gastroparesis. Also, case reports are used in summarizing safety. The control comparator groups included placebo or other prokinetic drugs (metoclopramide and cisapride). Controlled clinical trials of domperidone's efficacy and safety as an antiemetic are also briefly examined. Although a variety of domperidone dosage forms have been marketed, data generated from trials using the 10-mg tablet are highlighted because this is the only dosage form available in Canada and is under investigation in the US.
DATA EXTRACTION:
Because symptoms do not correlate with objective measures of gastrointestinal motility and they are the primary reason that patients with motility disorders seek treatment, the primary outcome extracted from the clinical studies was symptomatic response to treatment. Safety and efficacy between domperidone and placebo, metoclopramide, or cisapride were compared.
DATA SYNTHESIS:
Domperidone, a peripheral dopamine2-receptor antagonist, regulates the motility of gastric and small intestinal smooth muscle and has been shown to have some effects on the motor function of the esophagus. It also has antiemetic activity as a result of blockade of dopamine receptors in the chemoreceptor trigger zone. In controlled clinical trials, domperidone provided better relief of symptoms (anorexia, nausea, vomiting, abdominal pain, early satiety, bloating, distension) than placebo in patients with symptoms of diabetic gastropathy; symptomatic improvement was similar with domperidone and metoclopramide or cisapride. Domperidone also provided short-term relief of symptoms in patients with dyspepsia or gastroesophageal reflux, prevented nausea and vomiting associated with emetogenic chemotherapy, and prevented the gastrointestinal and emetic adverse effects of antiparkinsonian drugs. Because very little domperidone crosses the blood–brain barrier, reports of central nervous system adverse effects, such as dystonic reaction |
| doi_str_mv | 10.1345/aph.18003 |
| format | Article |
| fullrecord | <record><control><sourceid>sage_pubme</sourceid><recordid>TN_cdi_pubmed_primary_10332535</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.18003</sage_id><sourcerecordid>10.1345_aph.18003</sourcerecordid><originalsourceid>FETCH-LOGICAL-h278t-83c16ae81261c658d05af1836ac93a0460724e34af251673fe9dea3d412c3bbf3</originalsourceid><addsrcrecordid>eNpFkMtOwzAQRS0EoqWw4AdQFsAuZezJkxWoPKVKbGBtTR0ncdU8ZKeK-ve4FMRq7uLozsxh7JLDnGMU31Ffz3kGgEdsyuNIhIlI4dhnSCAEkcGEnTm3BoCci_yUTTggihjjKXt46ppeW1N0rb4PKNjnvtaWNptdQGowbRUUXU-NabUIrVa6HzobUDtQ1bXGDefspKSN0xe_c8a-Xp4_F2_h8uP1ffG4DGuRZkOYoeIJ6YyLhKskzgqIqeQZJqRyJIgSSEWkMaJSxDxJsdR5oQmLiAuFq1WJM3Z16O23q0YXsremIbuTf6944PoXIKdoU1pqlXH_XJohpOCx2wPmqNJy3W1t68_2NXKvUnqV8kelB28OYG2qejRWS9d4K349l-M4IspIRiLHb9qVb9Y</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Domperidone: a peripherally acting dopamine2-receptor antagonist</title><source>SAGE Publications</source><source>MEDLINE</source><creator>Barone, JA</creator><creatorcontrib>Barone, JA</creatorcontrib><description>OBJECTIVE:
To review the pharmacology, pharmacokinetics, efficacy, and safety of domperidone in the treatment of gastrointestinal motility disorders and emesis.
DATA SOURCES:
MEDLINE and Excerpta Medica online databases were searched to identify published reports.
STUDY SELECTION:
Domperidone has been marketed worldwide outside the US since 1978, and extensive clinical data for this drug are available. This review focuses on the clinical experience from controlled studies of domperidone in the treatment of motility disorders, particularly diabetic gastroparesis. Also, case reports are used in summarizing safety. The control comparator groups included placebo or other prokinetic drugs (metoclopramide and cisapride). Controlled clinical trials of domperidone's efficacy and safety as an antiemetic are also briefly examined. Although a variety of domperidone dosage forms have been marketed, data generated from trials using the 10-mg tablet are highlighted because this is the only dosage form available in Canada and is under investigation in the US.
DATA EXTRACTION:
Because symptoms do not correlate with objective measures of gastrointestinal motility and they are the primary reason that patients with motility disorders seek treatment, the primary outcome extracted from the clinical studies was symptomatic response to treatment. Safety and efficacy between domperidone and placebo, metoclopramide, or cisapride were compared.
DATA SYNTHESIS:
Domperidone, a peripheral dopamine2-receptor antagonist, regulates the motility of gastric and small intestinal smooth muscle and has been shown to have some effects on the motor function of the esophagus. It also has antiemetic activity as a result of blockade of dopamine receptors in the chemoreceptor trigger zone. In controlled clinical trials, domperidone provided better relief of symptoms (anorexia, nausea, vomiting, abdominal pain, early satiety, bloating, distension) than placebo in patients with symptoms of diabetic gastropathy; symptomatic improvement was similar with domperidone and metoclopramide or cisapride. Domperidone also provided short-term relief of symptoms in patients with dyspepsia or gastroesophageal reflux, prevented nausea and vomiting associated with emetogenic chemotherapy, and prevented the gastrointestinal and emetic adverse effects of antiparkinsonian drugs. Because very little domperidone crosses the blood–brain barrier, reports of central nervous system adverse effects, such as dystonic reactions, are rare.
CONCLUSIONS:
Domperidone is a unique gastrokinetic and antiemetic drug. Because of its favorable safety profile, domperidone appears to be an attractive alternative to metoclopramide. In the management of diabetic gastropathy, domperidone's antiemetic activity distinguishes it from cisapride.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.18003</identifier><identifier>PMID: 10332535</identifier><identifier>CODEN: APHRER</identifier><language>eng</language><publisher>Cincinnati, OH: Harvey Whitney Books</publisher><subject>Animals ; Biological and medical sciences ; Data Collection ; Diabetes Mellitus - drug therapy ; Digestive system ; Domperidone - adverse effects ; Domperidone - pharmacology ; Domperidone - therapeutic use ; Dopamine Antagonists - pharmacology ; Dopamine Antagonists - therapeutic use ; Drug Interactions ; Gastrointestinal Diseases - drug therapy ; Gastrointestinal Motility - drug effects ; Gastroparesis - drug therapy ; Humans ; Medical sciences ; Parkinson Disease - drug therapy ; Pharmacology. Drug treatments ; Vomiting - drug therapy</subject><ispartof>Annals of Pharmacotherapy, 1999-04, Vol.33 (4), p.429-440</ispartof><rights>1999 SAGE Publications</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1345/aph.18003$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1345/aph.18003$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>313,314,776,780,788,21798,27899,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1783070$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10332535$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barone, JA</creatorcontrib><title>Domperidone: a peripherally acting dopamine2-receptor antagonist</title><title>Annals of Pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>OBJECTIVE:
To review the pharmacology, pharmacokinetics, efficacy, and safety of domperidone in the treatment of gastrointestinal motility disorders and emesis.
DATA SOURCES:
MEDLINE and Excerpta Medica online databases were searched to identify published reports.
STUDY SELECTION:
Domperidone has been marketed worldwide outside the US since 1978, and extensive clinical data for this drug are available. This review focuses on the clinical experience from controlled studies of domperidone in the treatment of motility disorders, particularly diabetic gastroparesis. Also, case reports are used in summarizing safety. The control comparator groups included placebo or other prokinetic drugs (metoclopramide and cisapride). Controlled clinical trials of domperidone's efficacy and safety as an antiemetic are also briefly examined. Although a variety of domperidone dosage forms have been marketed, data generated from trials using the 10-mg tablet are highlighted because this is the only dosage form available in Canada and is under investigation in the US.
DATA EXTRACTION:
Because symptoms do not correlate with objective measures of gastrointestinal motility and they are the primary reason that patients with motility disorders seek treatment, the primary outcome extracted from the clinical studies was symptomatic response to treatment. Safety and efficacy between domperidone and placebo, metoclopramide, or cisapride were compared.
DATA SYNTHESIS:
Domperidone, a peripheral dopamine2-receptor antagonist, regulates the motility of gastric and small intestinal smooth muscle and has been shown to have some effects on the motor function of the esophagus. It also has antiemetic activity as a result of blockade of dopamine receptors in the chemoreceptor trigger zone. In controlled clinical trials, domperidone provided better relief of symptoms (anorexia, nausea, vomiting, abdominal pain, early satiety, bloating, distension) than placebo in patients with symptoms of diabetic gastropathy; symptomatic improvement was similar with domperidone and metoclopramide or cisapride. Domperidone also provided short-term relief of symptoms in patients with dyspepsia or gastroesophageal reflux, prevented nausea and vomiting associated with emetogenic chemotherapy, and prevented the gastrointestinal and emetic adverse effects of antiparkinsonian drugs. Because very little domperidone crosses the blood–brain barrier, reports of central nervous system adverse effects, such as dystonic reactions, are rare.
CONCLUSIONS:
Domperidone is a unique gastrokinetic and antiemetic drug. Because of its favorable safety profile, domperidone appears to be an attractive alternative to metoclopramide. In the management of diabetic gastropathy, domperidone's antiemetic activity distinguishes it from cisapride.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Data Collection</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Digestive system</subject><subject>Domperidone - adverse effects</subject><subject>Domperidone - pharmacology</subject><subject>Domperidone - therapeutic use</subject><subject>Dopamine Antagonists - pharmacology</subject><subject>Dopamine Antagonists - therapeutic use</subject><subject>Drug Interactions</subject><subject>Gastrointestinal Diseases - drug therapy</subject><subject>Gastrointestinal Motility - drug effects</subject><subject>Gastroparesis - drug therapy</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Parkinson Disease - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Vomiting - drug therapy</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtOwzAQRS0EoqWw4AdQFsAuZezJkxWoPKVKbGBtTR0ncdU8ZKeK-ve4FMRq7uLozsxh7JLDnGMU31Ffz3kGgEdsyuNIhIlI4dhnSCAEkcGEnTm3BoCci_yUTTggihjjKXt46ppeW1N0rb4PKNjnvtaWNptdQGowbRUUXU-NabUIrVa6HzobUDtQ1bXGDefspKSN0xe_c8a-Xp4_F2_h8uP1ffG4DGuRZkOYoeIJ6YyLhKskzgqIqeQZJqRyJIgSSEWkMaJSxDxJsdR5oQmLiAuFq1WJM3Z16O23q0YXsremIbuTf6944PoXIKdoU1pqlXH_XJohpOCx2wPmqNJy3W1t68_2NXKvUnqV8kelB28OYG2qejRWS9d4K349l-M4IspIRiLHb9qVb9Y</recordid><startdate>199904</startdate><enddate>199904</enddate><creator>Barone, JA</creator><general>Harvey Whitney Books</general><general>SAGE Publications</general><general>Whitney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>199904</creationdate><title>Domperidone: a peripherally acting dopamine2-receptor antagonist</title><author>Barone, JA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h278t-83c16ae81261c658d05af1836ac93a0460724e34af251673fe9dea3d412c3bbf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Data Collection</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Digestive system</topic><topic>Domperidone - adverse effects</topic><topic>Domperidone - pharmacology</topic><topic>Domperidone - therapeutic use</topic><topic>Dopamine Antagonists - pharmacology</topic><topic>Dopamine Antagonists - therapeutic use</topic><topic>Drug Interactions</topic><topic>Gastrointestinal Diseases - drug therapy</topic><topic>Gastrointestinal Motility - drug effects</topic><topic>Gastroparesis - drug therapy</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Parkinson Disease - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Vomiting - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barone, JA</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Annals of Pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barone, JA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Domperidone: a peripherally acting dopamine2-receptor antagonist</atitle><jtitle>Annals of Pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>1999-04</date><risdate>1999</risdate><volume>33</volume><issue>4</issue><spage>429</spage><epage>440</epage><pages>429-440</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><coden>APHRER</coden><abstract>OBJECTIVE:
To review the pharmacology, pharmacokinetics, efficacy, and safety of domperidone in the treatment of gastrointestinal motility disorders and emesis.
DATA SOURCES:
MEDLINE and Excerpta Medica online databases were searched to identify published reports.
STUDY SELECTION:
Domperidone has been marketed worldwide outside the US since 1978, and extensive clinical data for this drug are available. This review focuses on the clinical experience from controlled studies of domperidone in the treatment of motility disorders, particularly diabetic gastroparesis. Also, case reports are used in summarizing safety. The control comparator groups included placebo or other prokinetic drugs (metoclopramide and cisapride). Controlled clinical trials of domperidone's efficacy and safety as an antiemetic are also briefly examined. Although a variety of domperidone dosage forms have been marketed, data generated from trials using the 10-mg tablet are highlighted because this is the only dosage form available in Canada and is under investigation in the US.
DATA EXTRACTION:
Because symptoms do not correlate with objective measures of gastrointestinal motility and they are the primary reason that patients with motility disorders seek treatment, the primary outcome extracted from the clinical studies was symptomatic response to treatment. Safety and efficacy between domperidone and placebo, metoclopramide, or cisapride were compared.
DATA SYNTHESIS:
Domperidone, a peripheral dopamine2-receptor antagonist, regulates the motility of gastric and small intestinal smooth muscle and has been shown to have some effects on the motor function of the esophagus. It also has antiemetic activity as a result of blockade of dopamine receptors in the chemoreceptor trigger zone. In controlled clinical trials, domperidone provided better relief of symptoms (anorexia, nausea, vomiting, abdominal pain, early satiety, bloating, distension) than placebo in patients with symptoms of diabetic gastropathy; symptomatic improvement was similar with domperidone and metoclopramide or cisapride. Domperidone also provided short-term relief of symptoms in patients with dyspepsia or gastroesophageal reflux, prevented nausea and vomiting associated with emetogenic chemotherapy, and prevented the gastrointestinal and emetic adverse effects of antiparkinsonian drugs. Because very little domperidone crosses the blood–brain barrier, reports of central nervous system adverse effects, such as dystonic reactions, are rare.
CONCLUSIONS:
Domperidone is a unique gastrokinetic and antiemetic drug. Because of its favorable safety profile, domperidone appears to be an attractive alternative to metoclopramide. In the management of diabetic gastropathy, domperidone's antiemetic activity distinguishes it from cisapride.</abstract><cop>Cincinnati, OH</cop><pub>Harvey Whitney Books</pub><pmid>10332535</pmid><doi>10.1345/aph.18003</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1060-0280 |
| ispartof | Annals of Pharmacotherapy, 1999-04, Vol.33 (4), p.429-440 |
| issn | 1060-0280 1542-6270 |
| language | eng |
| recordid | cdi_pubmed_primary_10332535 |
| source | SAGE Publications; MEDLINE |
| subjects | Animals Biological and medical sciences Data Collection Diabetes Mellitus - drug therapy Digestive system Domperidone - adverse effects Domperidone - pharmacology Domperidone - therapeutic use Dopamine Antagonists - pharmacology Dopamine Antagonists - therapeutic use Drug Interactions Gastrointestinal Diseases - drug therapy Gastrointestinal Motility - drug effects Gastroparesis - drug therapy Humans Medical sciences Parkinson Disease - drug therapy Pharmacology. Drug treatments Vomiting - drug therapy |
| title | Domperidone: a peripherally acting dopamine2-receptor antagonist |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T14%3A52%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Domperidone:%20a%20peripherally%20acting%20dopamine2-receptor%20antagonist&rft.jtitle=Annals%20of%20Pharmacotherapy&rft.au=Barone,%20JA&rft.date=1999-04&rft.volume=33&rft.issue=4&rft.spage=429&rft.epage=440&rft.pages=429-440&rft.issn=1060-0280&rft.eissn=1542-6270&rft.coden=APHRER&rft_id=info:doi/10.1345/aph.18003&rft_dat=%3Csage_pubme%3E10.1345_aph.18003%3C/sage_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/10332535&rft_sage_id=10.1345_aph.18003&rfr_iscdi=true |